Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma

Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections of the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe in renal-cell carcinoma. Here, we assessed ilixadencel as a single agent and combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizell, Magnus, Sternby Eilard, Malin, Andersson, Mats, Andersson, Bengt, Karlsson-Parra, Alex, Suenaert, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348253/
https://www.ncbi.nlm.nih.gov/pubmed/30719425
http://dx.doi.org/10.3389/fonc.2019.00019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348253/
https://www.ncbi.nlm.nih.gov/pubmed/30719425
http://dx.doi.org/10.3389/fonc.2019.00019

Ejemplares similares